J&J, Gen­mab strength­en case for Darza­lex in front­line mul­ti­ple myelo­ma with fresh slate of PhI­II da­ta

J&J and Gen­mab of­fered a snap­shot of the Phase III da­ta that got Darza­lex its pri­or­i­ty re­view for front­line use late last week, high­light­ing how adding the block­buster mul­ti­ple myelo­ma drug to a chemother­a­py reg­i­men im­proved the com­plete re­sponse rate. The part­ners are now ready to ex­pound on the full ex­tent of that ben­e­fit with some num­bers on pro­gres­sion-free sur­vival.

The re­sults of the CAS­SIOPEIA study were pub­lished in The Lancet amid a flood of da­ta from AS­CO, where Sanofi al­so de­lin­eat­ed a case for its ri­val an­ti-CD38 ther­a­py, isat­ux­imab, by com­par­ing a com­bo with po­ma­lido­mide and dex­am­etha­sone against the chemo/cor­ti­cos­teroid alone.

Philippe More­au In­ter­na­tion­al Myelo­ma So­ci­ety

“There is a need for new treat­ment op­tions for new­ly di­ag­nosed pa­tients, po­ten­tial­ly in­clud­ing this com­bi­na­tion ther­a­py with dara­tu­mum­ab,” said Philippe More­au, pri­ma­ry in­ves­ti­ga­tor and head of the hema­tol­ogy de­part­ment at the Uni­ver­si­ty Hos­pi­tal of Nantes, France, in a state­ment. “This study adds to the grow­ing body of ev­i­dence for dara­tu­mum­ab in the front­line set­ting.”

As pre­vi­ous­ly re­port­ed, the group re­ceiv­ing Darza­lex plus the stan­dard of care VTD — Vel­cade(borte­zomib), thalido­mide and dex­am­etha­sone — notched a strin­gent com­plete re­sponse rate of 29% 100 days af­ter their au­tol­o­gous stem cell trans­plant, ver­sus 20% in the VTD arm (odds Ra­tio = 1.60; p<0.0010).

Fur­ther­more, DARZA­LEX-VTD in­creased the rate of very good par­tial re­sponse or bet­ter (83% ver­sus 78%, p<0.0239) and com­plete re­sponse or bet­ter (39% ver­sus 26%, p<0.0001).

Then there’s the sec­ond, on­go­ing part of the 1085-pa­tient study mea­sur­ing PFS in the pa­tients who show at least a par­tial re­sponse, the me­di­an for which has not been reached in ei­ther arm. But the 18-month PFS rate for the com­bo group was 93% — a sig­nif­i­cant im­prove­ment from VTD’s 85% ac­cord­ing to J&J. Haz­ard ra­tio came in at 0.47 with p<0.0001.

John Reed Sanofi

As J&J and Gen­mab await a de­ci­sion on their sBLA in Sep­tem­ber, Sanofi has a foot in US and EU reg­u­la­tors’ door for isat­ux­imab’s first ap­proval. Their drug scored a clear win on pro­gres­sion-free sur­vival for re­lapsed or re­frac­to­ry pa­tients, with 11.53 months for the com­bi­na­tion of isat­ux­imab and pom-dex com­pared to 6.47 months for pom-dex alone. The p-val­ue was 0.001.

The com­bi­na­tion al­so scored a 60% over­all re­sponse rate, com­pared to 35% for pom-dex alone — al­so sta­tis­ti­cal­ly sig­nif­i­cant.

Sanofi R&D chief John Reed con­tends that their drug, a late-stage fa­vorite in his plan to re­vamp the phar­ma gi­ant’s on­col­o­gy group, “has fea­tures that dif­fer­en­ti­ate it from dara­tu­mum­ab.” For in­stance, it di­rect­ly in­duces apop­to­sis in myelo­ma cells, hit­ting the tu­mor mi­croen­vi­ron­ment.

Ex­pect ag­gres­sive moves in­to front­line and sec­ond-line ter­ri­to­ry to fol­low, Reed told End­points News at AS­CO as he en­vi­sions a $3 bil­lion mar­ket op­por­tu­ni­ty. But J&J and an al­most pub­lic Gen­mab are com­ing to the de­fense pre­pared.

Im­age: Shut­ter­stock

As­traZeneca trum­pets the 'mo­men­tous' da­ta they found for Tagris­so in an ad­ju­vant set­ting for NSCLC — but many of the ex­perts aren’t cheer­ing along

AstraZeneca is rolling out the big guns this evening to provide a salute to their ADAURA data on Tagrisso at ASCO.

Cancer R&D chief José Baselga calls the disease-free survival data for their drug in an adjuvant setting of early stage, epidermal growth factor receptor-mutated NSCLC patients following surgery “momentous.” Roy Herbst, the principal investigator out of Yale, calls it “transformative.”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 81,800+ biopharma pros reading Endpoints daily — and it's free.

Ab­b­Vie wins an ap­proval in uter­ine fi­broid-as­so­ci­at­ed heavy bleed­ing. Are ri­vals My­ovant and Ob­sE­va far be­hind?

Women expel on average about 2 to 3 tablespoons of blood during their time of the month. But with uterine fibroids, heavy bleeding is typical — a third of a cup or more. Drugmakers have been working on oral therapies to try and stem the flow, and as expected, AbbVie and their partners at Neurocrine Biosciences are the first to make it across the finish line.

Known chemically as elagolix, the drug is already approved as a treatment for endometriosis under the brand name Orilissa. It targets the GnRH receptor to decrease the production of estrogen and progesterone.

David Chang, Allogene CEO (Jeff Rumans)

Head­ed to PhII: Al­lo­gene CEO David Chang com­pletes a pos­i­tive ear­ly snap­shot of their off-the-shelf CAR-T pi­o­neer

Allogene CEO David Chang has completed the upbeat first portrait of the biotech’s off-the-shelf CAR-T contender ALLO-501 at virtual ASCO today, keeping all eyes on a drug that will now try to go on to replace the first-wave personalized pioneers he helped create.

The overall response rate outlined in Allogene’s abstract for treatment-resistant patients with non-Hodgkin lymphoma slipped a little from the leadup, but if you narrow the patient profile to treatment-naïve patients — removing the 3 who had previous CAR-T therapy who didn’t respond, leaving 16 — the ORR lands at 75% with a 44% complete response rate. And 9 of the 12 responders remained in response at the data cutoff, offering a glimpse on durability that still has a long way to go before it can be completely nailed down.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 81,800+ biopharma pros reading Endpoints daily — and it's free.

Pablo Legorreta, founder and CEO of Royalty Pharma AG, speaks at the annual Milken Institute Global Conference in Beverly Hills, California (Patrick T. Fallon/Bloomberg via Getty Images)

Cap­i­tal­iz­ing Pablo: The world’s biggest drug roy­al­ty buy­er is go­ing pub­lic. And the low-key CEO di­vulges a few se­crets along the way

Pablo Legorreta is one of the most influential players in biopharma you likely never heard of.

Over the last 24 years, Legorreta’s Royalty Pharma group has become, by its own reckoning, the biggest buyer of drug royalties in the world. The CEO and founder has bought up a stake in a lengthy list of the world’s biggest drug franchises, spending $18 billion in the process — $2.2 billion last year alone. And he’s become one of the best-paid execs in the industry, reaping $28 million from the cash flow last year while reserving 20% of the cash flow, less expenses, for himself.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 81,800+ biopharma pros reading Endpoints daily — and it's free.

Fabrice Chouraqui, Cellarity CEO-partner (LinkedIn)

Drug de­vel­op­er, Big Phar­ma com­mer­cial ex­ec, now an up­start biotech chief — Fab­rice Chouraqui is ready to try some­thing new as a ‘CEO-part­ner’ at Flag­ship

Fabrice Chouraqui’s career has taken some big twists along his life journey. He got his PharmD at Université Paris Descartes and jumped into the drug development game for a bit. Then he took a sharp turn and went back to school to get his MBA at Insead before returning to pharma on the commercial side.

Twenty years later, after steadily rising through the ranks and journeying the globe to nab a top job as president of US pharma for the Basel-based Novartis, Chouraqui exited in another career switch. And now he’s headed into a hybrid position as a CEO-partner at Flagship, where he’ll take a shot at leading Cellarity — one of the VC’s latest paradigm-changing companies of the groundbreaking model that aspires to deliver a new platform to the world of drug R&D.

Paul Hudson, Sanofi CEO (Getty Images)

Sanofi CEO Paul Hud­son has $23B burn­ing a hole in his pock­et. And here are some hints on how he plans to spend that

Sanofi has reaped $11.1 billion after selling off a big chunk of its Regeneron stock at $515 a share. And now everyone on the M&A side of the business is focused on how CEO Paul Hudson plans to spend it.

After getting stung in France for some awkward politicking — suggesting the US was in the front of the line for Sanofi’s vaccines given American financial support for their work, versus little help from European powers — Hudson now has the much more popular task of managing a major cash cache to pull off something in the order of a big bolt-on. Or two.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 81,800+ biopharma pros reading Endpoints daily — and it's free.

Roger Perlmutter, Merck R&D chief (YouTube)

UP­DAT­ED: Backed by BAR­DA, Mer­ck jumps in­to Covid-19: buy­ing out a vac­cine, part­ner­ing on an­oth­er and adding an­tivi­ral to the mix

Merck execs are making a triple play in a sudden leap into the R&D campaign against Covid-19. And they have more BARDA cash backing them up on the move.

Tuesday morning the pharma giant simultaneously announced plans to buy an Austrian biotech that has been working on a preclinical vaccine candidate, added a collaboration on another vaccine with the nonprofit IAVI and inked a deal with Ridgeback Biotherapeutics on an early-stage antiviral.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 81,800+ biopharma pros reading Endpoints daily — and it's free.

As­traZeneca’s $7B ADC suc­ceeds where Roche failed, im­prov­ing sur­vival in gas­tric can­cer

Another day, another win for Enhertu.

The antibody-drug conjugate AstraZeneca promised up-to $7 billion to partner on has had a quite a few months, beginning with splashy results in a Phase II breast cancer trial, a rapid approval and, earlier this month, breakthrough designations in both non-small cell lung cancer and gastric cancer.

Now, at ASCO, the British pharma and their Japanese partner, Daiichi Sankyo, have shown off the data that led to the gastric cancer designation, which they’ll take back to the FDA. In a pivotal, 187-person Phase II trial, Enhertu shrunk tumors in 42.9% of third-line patients with HER2-positive stomach cancer, compared with 12.5% in a control arm where doctors prescribed their choice of therapy. Progression-free survival was 5.4 months for Enhertu compared to 3.5 months for the control.

Once a gem, now just a rock, Take­da punts PhI­II IBD drug as ri­vals mus­cle ahead

Back in 2016, when then-Shire CEO Flemming Ørnskov picked up a promising clinical-stage IBD drug from Pfizer, the Boston-based biotech dubbed it SHP647 and moved it into the gem section of the pipeline, with rosy expectations of registration-worthy Phase III data ahead.

This was a drug that the EC wanted Takeda to commit to selling off before it gave their blessing to its acquisition of Shire, to settle some deep-seated concerns revolving around the potential market overlap with their blockbuster rival Entyvio. And Takeda, which took on a heavy debt load to buy Shire, clearly wanted the cash to pay down debt.